The Cooper Companies
Q2 2022 Earnings Call
Jun 02, 2022, 5:00 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to The Cooper Companies second quarter 2022 earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Kim Duncan, vice president of investor relations and risk management.
Please go ahead, ma'am.
Kim Duncan -- Vice President of Investor Relations and Risk Management
Good afternoon, and welcome to The Cooper Companies second quarter 2022 earnings conference call. During today's call, we will discuss the results and guidance included in the earnings release and then use the remaining time for questions. Our presenters on today's call are Al White, president and chief executive officer; and Brian Andrews, chief financial officer and treasurer. Before we begin, I'd like to remind you that this conference call contains forward-looking statements, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and acquisitions, integration of any acquisitions or their anticipated benefits.
Al White -- President and Chief Executive Officer
Great. Thank you, Kim, and welcome, everyone, to our second quarter conference call. Let me start by highlighting that our businesses are performing extremely well. Both CooperVision and CooperSurgical posted strong revenue growth, gained share and are continuing to see strong momentum.
We're successfully managing through a variety of challenges from supply chain to COVID restrictions in China and we're maintaining our market-leading growth rates. So I'm really pleased with how the year is progressing. For the full year, we're increasing our organic revenue guidance for both businesses by incorporating our Q2 outperformance and the strength we're continuing to see. Moving to the quarter.
Consolidated revenues reached an all-time high of $830 million, with CooperVision at $554 million, up 12% organically and CooperSurgical at $276 million, up 40% as reported or up 6% organically. The quarter was led by strength in CooperVision's daily silicone hydrogel portfolio and our myopia management products and CooperSurgical's fertility business, which posted another double-digit growth quarter. Non-GAAP earnings per share were $3.24, and Brian will provide the details, but this quarter was negatively impacted by FX in our contact lens solutions business. Moving to CooperVision and reporting all percentages on an organic basis.